About this condition
Tinnitus — Genetic Factors
Tinnitus (phantom auditory perception) affects approximately 15-20% of adults, with significant tinnitus in 1-2%. Twin studies estimate 30-40% heritability. Genetic contributions include: hearing loss susceptibility genes (GJB2, KCNQ4, KCNE1, SLC26A4), noise-induced hearing loss vulnerability variants (KCNE1, CDH23), and central auditory pathway genes influencing neural hyperexcitability (BDNF, SLC6A4/serotonin transporter).
Several genetic hearing loss conditions present primarily with tinnitus: otosclerosis (estimated 50-70% heritability, TGFB1, RELN candidate genes), Ménière's disease (episodic tinnitus with vertigo), and DFNA-type autosomal dominant hearing loss (progressive high-frequency loss with tinnitus). Molecular genetic testing can differentiate these treatable conditions from primary tinnitus.
Emerging pharmacogenomic relevance: tinnitus treatment response may be influenced by serotonin transporter (SLC6A4) variants (response to SSRIs), GABA receptor variants (response to gabapentin/benzodiazepines), and glutamate receptor variants (response to emerging NMDA-targeted therapies). As tinnitus pharmacotherapy advances, pharmacogenomic profiling may guide personalized treatment selection.
Tinnitus is often the FIRST symptom of genetic hearing loss. If tinnitus runs in your family, genetic hearing loss testing can identify the underlying cause — some of which are treatable (otosclerosis, Ménière's, stapes surgery).
- Gene locus
- GJB2 (13q12.11), KCNQ4 (1p34.2), KCNE1 (21q22.12), CDH23 (10q22.1), SLC6A4 (17q11.2)
